Home/Pipeline/HER3-Targeting Radiotherapy

HER3-Targeting Radiotherapy

Solid Tumors

PreclinicalResearch collaboration with AVEO

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Research collaboration with AVEO

Company

Actinium Pharmaceuticals

About Actinium Pharmaceuticals

Actinium Pharmaceuticals is focused on developing innovative, targeted radiotherapies to address unmet needs in oncology, particularly in hematologic malignancies and solid tumors. The company leverages its expertise with the Actinium-225 payload to create differentiated therapies, with its lead candidates in advanced clinical development. Strategic partnerships, such as the licensing deal with Immedica for Iomab-B in Europe, and collaborations with Astellas and AVEO, support its platform expansion and validate its technology.

View full company profile

Therapeutic Areas

Oncology Hematology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active